ESMO 2018 | Treating oligometastatic CRPC with radiation to delay hormonal therapy

Evidence from the recent SPARTAN and PROSPER trials indicate the use of apalutamide and enzalutamide in M0 castration-resistant prostate cancer. Joe O’Sullivan, MD, of the Queen’s University Belfast, Belfast, UK, questions whether this new subgroup of men exist, highlighting the implications of patients receiving over-treatment, in addition to being treated too early. Prof. O’Sullivan makes particular mention of the negative impacts on quality of life from these drugs, where there is no evidence to suggest they improve survival, and suggests the treatment of oliometastatic disease with radiation to combat this problem (CORE; NCT02759783). This video was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.